 |
Gilenia, the oral drug for relapsing MS formerly known as FTY720, has been granted priority review by the US Food and Drug Administration (FDA). An approval decision could take as little as six months.
To read more, as reported by the US National MS Society, click here.
Source: US National MS Society
|
